Login to Your Account



Nektar bags $150M up front in Lilly autoimmune alliance

By Marie Powers
New Editor

Monday, July 24, 2017

Nektar Therapeutics Inc. continued its string of partnerships by hooking Eli Lilly and Co. as a collaborator to co-develop NKTR-358, a candidate advanced from inception to the clinic in a mere 15 months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription